In my opinion, ANI Pharmaceuticals should beat earnings and revenue estimates for the 13th consecutive quarter. Purified Cortrophin sales should lead the way. ANIP should announce approval and ...
ANI Pharmaceuticals delivered strong Q4 and FY25 results, with revenue up 30% and record Cortrophin Gel growth. I see near-term risks from seasonally weaker Cortrophin sales due to insurance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results